Use of cabozantinib in a patient with EGFR-mutated non–small-cell lung cancer harboring acquired CCDC6-RET fusion

Young Kwang Chae*, Pedro Viveiros, Caio T. Heleno, Haris Bilal, Bhoomika A. Sukhadia, Michael S. Oh, Muhamad Mubbashir Sheikh, Wade T. Iams, Lee Chun Park

*Corresponding author for this work

Research output: Contribution to journalArticle

Original languageEnglish (US)
JournalJCO Precision Oncology
Volume3
DOIs
StatePublished - Jan 1 2019

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Chae, Y. K., Viveiros, P., Heleno, C. T., Bilal, H., Sukhadia, B. A., Oh, M. S., Sheikh, M. M., Iams, W. T., & Park, L. C. (2019). Use of cabozantinib in a patient with EGFR-mutated non–small-cell lung cancer harboring acquired CCDC6-RET fusion. JCO Precision Oncology, 3. https://doi.org/10.1200/PO.18.00295